Since endothelial dysfunction, elevated hsCRP, IL-1β, and IL-6 concentrations have all been associated with increased cardiovascular risk [26–28, 38, 42–44], and since lowering of hsCRP and IL-6 via anti-IL-1β strategies is associated with reduced rates of major adverse cardiovascular events [45, 46], these data suggest that gout treatment with colchicine+XOI may lower cardiovascular risk. The gene discussed is IL1B; the disease is endothelial dysfunction.